Elon Musk Emphasizes the Potential of GLP-1 Drugs, Calls for Solutions to Healthcare Costs

Elon Musk recently made a statement on social media platform X, highlighting the enormous potential of GLP-1 drugs in improving the health, extending the lifespan, and enhancing the quality of life for Americans. He pointed out that widespread use of these drugs could significantly reduce healthcare expenses in the U.S.

However, GLP-1 drugs currently face issues of supply shortages, high prices, and inadequate insurance coverage, making it difficult for many American consumers to access them. While the Biden administration is working to include obesity medications in Medicare and state Medicaid programs, Congress is also reviewing related legislation, which could greatly improve drug accessibility but might also lead to substantial additional expenses.

As the head of the "Department of Government Efficiency," Musk previously promised to cut trillions in federal spending. Nonetheless, he continues to advocate for GLP-1 drugs as an effective means of achieving long-term cost savings. He believes that since most healthcare expenditures occur in the final stages of life, and obesity is a significant contributor to many diseases, it is crucial to reduce the costs of GLP-1 drugs to very low levels.

Currently, Musk has not detailed how to achieve this goal, but analysts expect that as these drugs may soon qualify for price negotiations under Medicare, this could be a potential avenue for reducing their costs.